Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer
-
Published:2024-08-05
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Xu Pengfei, Yang Joy C.ORCID, Chen Bo, Ning Shu, Zhang Xiong, Wang Leyi, Nip Christopher, Shen Yuqiu, Johnson Oleta T.ORCID, Grigorean GabrielaORCID, Phinney BrettORCID, Liu Liangren, Wei Qiang, Corey EvaORCID, Tepper Clifford G.ORCID, Chen Hong-Wu, Evans Christopher P., Dall’Era Marc A., Gao Allen C., Gestwicki Jason E.ORCID, Liu ChengfeiORCID
Abstract
AbstractN-Myc is a key driver of neuroblastoma and neuroendocrine prostate cancer (NEPC). One potential way to circumvent the challenge of undruggable N-Myc is to target the protein homeostasis (proteostasis) system that maintains N-Myc levels. Here, we identify heat shock protein 70 (HSP70) as a top partner of N-Myc, which binds a conserved “SELILKR” motif and prevents the access of E3 ubiquitin ligase, STIP1 homology and U-box containing protein 1 (STUB1), possibly through steric hindrance. When HSP70’s dwell time on N-Myc is increased by treatment with the HSP70 allosteric inhibitor, STUB1 is in close proximity with N-Myc and becomes functional to promote N-Myc ubiquitination on the K416 and K419 sites and forms polyubiquitination chains linked by the K11 and K63 sites. Notably, HSP70 inhibition significantly suppressed NEPC tumor growth, increased the efficacy of aurora kinase A (AURKA) inhibitors, and limited the expression of neuroendocrine-related pathways.
Funder
U.S. Department of Health & Human Services | NIH | National Cancer Institute United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs
Publisher
Springer Science and Business Media LLC
Reference73 articles.
1. Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W. & Balch, W. E. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 78, 959–991 (2009). 2. Martínez-Jiménez, F., Muiños, F., López-Arribillaga, E., Lopez-Bigas, N. & Gonzalez-Perez, A. Systematic analysis of alterations in the ubiquitin proteolysis system reveals its contribution to driver mutations in cancer. Nat. Cancer 1, 122–135 (2020). 3. Liu, Y. & Ye, Y. Proteostasis regulation at the endoplasmic reticulum: a new perturbation site for targeted cancer therapy. Cell Res. 21, 867–883 (2011). 4. Balch, W. E., Morimoto, R. I., Dillin, A. & Kelly, J. W. Adapting proteostasis for disease intervention. Science 319, 916–919 (2008). 5. Gallo, L. H., Ko, J. & Donoghue, D. J. The importance of regulatory ubiquitination in cancer and metastasis. Cell Cycle 16, 634–648 (2017).
|
|